Biogen (NASDAQ:BIIB) Releases Earnings Results

Biogen (NASDAQ:BIIB) issued its quarterly earnings data on Wednesday. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.43 by $0.01, Zacks reports. Biogen had a return on equity of 14.98% and a net margin of 16.81%. Biogen updated its FY 2025 guidance to 15.250-16.250 EPS.

Biogen Stock Down 4.3 %

BIIB stock opened at $133.43 on Thursday. The company has a market cap of $19.44 billion, a price-to-earnings ratio of 12.05, a PEG ratio of 1.65 and a beta of -0.08. The firm has a 50-day moving average of $148.28 and a two-hundred day moving average of $174.33. Biogen has a 12 month low of $128.51 and a 12 month high of $238.00. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BIIB shares. William Blair reissued an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Wolfe Research assumed coverage on shares of Biogen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Piper Sandler downgraded shares of Biogen from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $315.00 to $138.00 in a report on Thursday, January 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Biogen in a report on Thursday, October 31st. Finally, Truist Financial decreased their price objective on shares of Biogen from $302.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Seventeen equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $221.65.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.